Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Rojo

Showing results (101-110 of 118) with videos related to

Pageof 12
Sort By:
Virchows Archiv : an International Journal of Pathology|December 5, 2019
Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH)J Palacios, M de la Hoya, B Bellosillo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2009
Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxelC Sessa, D Tosi, L Viganò, et al.
Archives of Gerontology and Geriatrics|June 12, 2020
The WHO active ageing pillars and its association with survival: Findings from a population-based study in SpainA I Hijas-Gómez, A Ayala, M P Rodríguez-García, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2002
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor typesJ Baselga, D Rischin, M Ranson, et al.
British Journal of Cancer|March 18, 2010
Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patientsC Montagut, M Iglesias, M Arumi, et al.
British Journal of Cancer|August 18, 2011
MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell linesE Arriola, I Cañadas, M Arumí-Uría, et al.
British Journal of Cancer|January 25, 2014
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trialE Alba, J Albanell, J de la Haba, et al.
Oncogene|October 5, 2010
DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancerV Moncho-Amor, I Ibañez de Cáceres, E Bandres, et al.
British Journal of Cancer|May 3, 2014
Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapyL del Puerto-Nevado, F Rojo, S Zazo, et al.
Water Research|April 12, 2019
Combining electrokinetic transport and bioremediation for enhanced removal of crude oil from contaminated marine sediments: Results of a long-term, mesocosm-scale experimentS Cappello, C Cruz Viggi, M Yakimov, et al.
Pageof 12

Showing results (101-110 of 118) with videos related to

Sort By:
Pageof 12
Virchows Archiv : an International Journal of Pathology|December 5, 2019
Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH)J Palacios, M de la Hoya, B Bellosillo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2009
Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxelC Sessa, D Tosi, L Viganò, et al.
Archives of Gerontology and Geriatrics|June 12, 2020
The WHO active ageing pillars and its association with survival: Findings from a population-based study in SpainA I Hijas-Gómez, A Ayala, M P Rodríguez-García, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2002
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor typesJ Baselga, D Rischin, M Ranson, et al.
British Journal of Cancer|March 18, 2010
Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patientsC Montagut, M Iglesias, M Arumi, et al.
British Journal of Cancer|August 18, 2011
MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell linesE Arriola, I Cañadas, M Arumí-Uría, et al.
British Journal of Cancer|January 25, 2014
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trialE Alba, J Albanell, J de la Haba, et al.
Oncogene|October 5, 2010
DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancerV Moncho-Amor, I Ibañez de Cáceres, E Bandres, et al.
British Journal of Cancer|May 3, 2014
Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapyL del Puerto-Nevado, F Rojo, S Zazo, et al.
Water Research|April 12, 2019
Combining electrokinetic transport and bioremediation for enhanced removal of crude oil from contaminated marine sediments: Results of a long-term, mesocosm-scale experimentS Cappello, C Cruz Viggi, M Yakimov, et al.
Pageof 12